Mitosis phase enrichment with identification of mitotic centromere-associated kinesin as a therapeutic target in castration-resistant prostate cancer

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Sircar, Kanishka ^a   Huang, Heng ^b   Hu, Limei ^a   Liu, Yuexin ^a   Dhillon, Jasreman ^a   Cogdell, David ^a   Aprikian, Armen ^c   Efstathiou, Eleni ^a   Navone, Nora ^a   Troncoso, Patricia ^a   Zhang, Wei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b University of Texas at Arlington   (United States)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KINESIN; MESSENGER RNA; MITOTIC CENTROMERE ASSOCIATED KINESIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANDROGEN; ANTINEOPLASTIC AGENT; KIF2C PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP; CENTROSOME ABERRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC DISORDER; GENETIC ENHANCEMENT; GENETIC IDENTIFICATION; GENETIC TRANSCRIPTION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; MITOSIS; MITOTIC CENTROMERE ASSOCIATED KINESIN GENE; MOUSE; NONHUMAN; ONCOGENE; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMALL CELL CARCINOMA; TUMOR XENOGRAFT; UPREGULATION; CANCER GRADING; CASTRATION; CENTROSOME; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROSTATE TUMOR;

ANDROGENS; ANTINEOPLASTIC AGENTS; CASTRATION; CENTROSOME; DRUG RESISTANCE, NEOPLASM; HUMANS; KINESIN; MALE; MITOSIS; MOLECULAR TARGETED THERAPY; NEOPLASM GRADING; PROSTATIC NEOPLASMS; UP-REGULATION;

EID: 84857173975     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031259     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer Statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512.
4. Agarwal N, Sonpavde G, Sternberg CN, (2011) Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer. Eur Urol.
5. Liu Q, Jernigan D, Zhang Y, Fatatis A, (2011) Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis. Chin J Cancer 30: 612-619.
6. Wang Q, Li W, Zhang Y, Yuan X, Xu K, et al. (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138: 245-256.
7. Prigent C, Dimitrov S, (2003) Phosphorylation of serine 10 in histone H3, what for? J Cell Sci 116: 3677-3685.
8. D'Assoro AB, Barrett SL, Folk C, Negron VC, Boeneman K, et al. (2002) Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness. Breast Cancer Res Treat 75: 25-34.
9. Yamamoto Y, Matsuyama H, Furuya T, Oga A, Yoshihiro S, et al. (2004) Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer. Clin Cancer Res 10: 6449-6455.
10. Gustafson LM, Gleich LL, Fukasawa K, Chadwell J, Miller MA, et al. (2000) Centrosome hyperamplification in head and neck squamous cell carcinoma: a potential phenotypic marker of tumor aggressiveness. Laryngoscope 110: 1798-1801.
11. Syed MI, Syed S, Minty F, Harrower S, Singh J, et al. (2009) Gamma tubulin: a promising indicator of recurrence in squamous cell carcinoma of the larynx. Otolaryngol Head Neck Surg 140: 498-504.
12. True L, Coleman I, Hawley S, Huang CY, Gifford D, et al. (2006) A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A 103: 10991-10996.
13. Knowlton AL, Lan W, Stukenberg PT, (2006) Aurora B is enriched at merotelic attachment sites, where it regulates MCAK. Curr Biol 16: 1705-1710.
14. Gnjatic S, Cao Y, Reichelt U, Yekebas EF, Nolker C, et al. (2010) NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. Int J Cancer 127: 381-393.
15. Shimo A, Tanikawa C, Nishidate T, Lin ML, Matsuda K, et al. (2008) Involvement of kinesin family member 2C/mitotic centromere-associated kinesin overexpression in mammary carcinogenesis. Cancer Sci 99: 62-70.
16. Blangy A, Lane HA, d'Herin P, Harper M, Kress M, et al. (1995) Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83: 1159-1169.
17. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, et al. (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286: 971-974.
18. Huszar D, Theoclitou ME, Skolnik J, Herbst R, (2009) Kinesin motor proteins as targets for cancer therapy. Cancer Metastasis Rev 28: 197-208.
19. Sanhaji M, Friel CT, Kreis NN, Kramer A, Martin C, et al. (2010) Functional and spatial regulation of mitotic centromere-associated kinesin by cyclin-dependent kinase 1. Mol Cell Biol 30: 2594-2607.
20. De S, Cipriano R, Jackson MW, Stark GR, (2009) Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res 69: 8035-8042.
21. Ganguly A, Yang H, Cabral F, (2011) Overexpression of mitotic centromere-associated Kinesin stimulates microtubule detachment and confers resistance to paclitaxel. Mol Cancer Ther 10: 929-937.
22. Harrison MR, Holen KD, Liu G, (2009) Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 7: 54-64.
23. Marcus AI, Peters U, Thomas SL, Garrett S, Zelnak A, et al. (2005) Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and-sensitive cancer cells. J Biol Chem 280: 11569-11577.
24. Hayashi N, Koller E, Fazli L, Gleave ME, (2008) Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity. Prostate 68: 1283-1295.
25. Davis DA, Sarkar SH, Hussain M, Li Y, Sarkar FH, (2006) Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line. BMC Cancer 6: 22.
26. Blagden SP, Molife LR, Seebaran A, Payne M, Reid AH, et al. (2008) A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. Br J Cancer 98: 894-899.
27. Beer TM, Goldman B, Synold TW, Ryan CW, Vasist LS, et al. (2008) Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer 6: 103-109.
28. Wiltshire C, Singh BL, Stockley J, Fleming J, Doyle B, et al. (2010) Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition. Mol Cancer Ther 9: 1730-1739.
29. Price ND, Trent J, El-Naggar AK, Cogdell D, Taylor E, et al. (2007) Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A 104: 3414-3419.
30. Efstathiou E, Troncoso P, Wen S, Do KA, Pettaway CA, et al. (2007) Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer. Clin Cancer Res 13: 1224-1231.
31. Jabbur JR, Zhang W, (2002) p53 Antiproliferative function is enhanced by aspartate substitution at threonine 18 and serine 20. Cancer Biol Ther 1: 277-283.